Cite

HARVARD Citation

    Sandborn, W. et al. (2010). Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut. 59 (11), pp. 1485-1492. [Online]. 
  
Back to record